Company profile for Celcuity

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD, to develop a better way to diagnose and treat the cellular abnormalities that drive tumor growth. Our team of drug development scientists, biochemists, molecular biologists, and diagnostics experts are advancing new targeted therapies for cancer using an integrated therapeutic and companion diagnostic strategy that leverages our CELsignia platform. This allow...
Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD, to develop a better way to diagnose and treat the cellular abnormalities that drive tumor growth. Our team of drug development scientists, biochemists, molecular biologists, and diagnostics experts are advancing new targeted therapies for cancer using an integrated therapeutic and companion diagnostic strategy that leverages our CELsignia platform. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
16305 – 36th Avenue North Suite 100 Minneapolis, MN 55446
Telephone
Telephone
763-473-0341
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/11/3204248/0/en/Celcuity-Presents-Updated-Results-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/11/26/3195029/0/en/Celcuity-To-Present-at-Upcoming-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/26/3195381/0/en/Celcuity-to-Present-Updated-Data-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3189580/0/en/Celcuity-Announces-Completion-of-Submission-of-Its-New-Drug-Application-to-the-U-S-FDA-for-Gedatolisib-in-HR-HER2-PIK3CA-Wild-Type-Advanced-Breast-Cancer.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186736/0/en/Celcuity-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181320/0/en/Celcuity-Inc-Schedules-Release-of-Third-Quarter-2025-Financial-Results-and-Webcast-Conference-Call.html

GLOBENEWSWIRE
05 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty